Co-secretion of growth hormone and prolactin defines a high-risk acromegaly phenotype
Authors' conclusion
GH/PRL-PitNETs demonstrated greater tumor burden and more pronounced structural invasiveness, resulting in a significantly lower likelihood of endocrinological remission.
Study context
- Population
- Patients with acromegaly who underwent surgery between 2018 and 2024
- Participants
- 188 patients
- Exposure
- GH/PRL-PitNETs vs GH-PitNETs
- GH/PRL-PitNETsn = 46
- GH-PitNETsn = 142reference
- Outcome
- Biochemical remission
Main finding
As reported in the abstract
Surgical remission rate
- Surgical remission rate lower in GH/PRL-PitNETs
- GH/PRL-PitNETs vs GH-PitNETs: P = 0.023
Observational data: associations, not effects.
Further findings
Tumor size and invasiveness
- GH/PRL-PitNETs significantly larger and more invasive than GH-PitNETs
Predictors of biochemical remission (multivariable Cox analysis)
- Tumor size and cavernous sinus invasion independently predicted inferior biochemical remission
Medical comorbidities
- Higher incidence of comorbidities such as hypertension and thyroid carcinoma in GH-PitNETs
Original publication
Co-secretion of growth hormone and prolactin defines a high-risk acromegaly phenotype. Pituitary. Published 18 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →